Skip to main content

Table 1 Patient demographic and clinical characteristics

From: EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

  Descriptive cohort (n = 103) Correlative cohort (n = 66) Anti-EGFR treated (n = 39)
  n % n % n %
Age (years)       
  Median 64   60   62  
  Range 38-88   38-81   38-77  
Smoking history       
  Never smokers 63 61 40 60 27 69
  Former smokers 8 8 5 8 4 10
  Current smokers 32 31 21 32 8 21
Stage       
  IIIB 30 29 17 26 11 28
  IV 73 71 49 74 28 72
Number of sites of metastases       
  1 16 16 18 27 9 23
  2 25 24 26 39 13 33
  ≥3 62 60 22 34 17 44
CNS metastases       
  Yes 14 14 12 18 7 18
  No 89 86 54 82 32 82
Previous surgery on primary       
  Yes 46 45 20 30 14 36
  No 57 55 46 70 25 64
Previous (neo-)adjuvant CT       
  Yes 9 9 5 8 4 10
  No 94 91 61 92 35 90
Previous adjuvant RT       
  Yes 4 4 2 4 3 8
  No 99 96 63 96 36 92
First-line CT regimen       
  Platinum + Paclitaxel 10 10 10 15 5 13
  Platinum + Gemcitabine 39 39 39 59 21 54
  Platinum + Pemetrexed 13 13 13 20 6 15
  Cisplatin + Vinorelbine 2 2 2 3 1 3
  Cisplatin-based triplet CT 2 2 2 3 2 5
  Single-agent CT* 26 26 - - 4 10
  Best supportive care only 8 8 - - - -
Anti-EGFR TKI treatment line       
  2 28 27 24 36 27 69
  ≥3 12 12 9 14 12 31
  1. Abbreviations: TKIs tyrosine-kinase inhibitors, ECOG Eastern Cooperative Oncology Group, CNS central nervous system, CT chemotherapy, RT radiotherapy. *Single agent platinum, gemcitabine, vinorelbine, pemetrexed.